Success Metrics

Clinical Success Rate

80.0%

Based on 8 completed trials

Completion Rate

80%(8/10)

Active Trials

0(0%)

Results Posted

50%(4 trials)

Terminated

2(15%)

Phase Distribution

Ph phase_3

23%

Ph not_applicable

Ph phase_1

38%

Ph phase_2

31%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

5(38.5%)

Phase 2Efficacy & side effects

4(30.8%)

Phase 3Large-scale testing

3(23.1%)

N/ANon-phased studies

1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(8)

Terminated(2)

Other(2)

Detailed Status

Completed8

Terminated2

unknown2

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 3

Trials by Phase

Phase 15 (38.5%)

Phase 24 (30.8%)

Phase 33 (23.1%)

N/A1 (7.7%)

Trials by Status

completed862%

terminated215%

not_yet_recruiting18%

unknown215%

Recent Activity

0 active trials

Showing 5 of 13

not_yet_recruitingphase_3

A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)

NCT07296445

terminatedphase_1

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

NCT02712905

completedphase_1

Clinical Trials (13)

Showing 13 of 13 trials

NCT07296445Phase 3

A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)

Not Yet Recruiting

NCT02712905Phase 1

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Terminated

NCT02751255Phase 1

Daratumumab in Combination With ATRA

Completed

NCT00482833Phase 3

Phase III Trial in Acute Promyelocytic Leukemia Patients

Completed

NCT01064557Not Applicable

"AIDA" Protocol (LAP 0493)

AIDA 2000 Guidelines

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Completed

NCT01237808Phase 3

Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

Completed

NCT01985477Phase 1

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Terminated

NCT00175812Phase 1

Differentiation Induction in Acute Myelogenous Leukemia

Completed

NCT01161550Phase 1

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

Completed

NCT00601796Phase 2

Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer